Recent Company News

• 05:05 AM ET Mar 18, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:08 AM ET Apr 01, 2025
  

  Vivesto announced positive preclinical efficacy data was obtained in an animal model of hematological cancer (SEK 0.25, 0.00)

• 02:18 AM ET Mar 31, 2025
  

  Vivesto signs agreement with Kazia Therapeutics to acquire full rights, including all intellectual property and trademarks rights for the drug candidate Cantrixil for $1M (SEK 0.24, 0.00)

• 02:19 AM ET Mar 18, 2025
  

  Vivesto licenses Apealea to China's Zhida Pharmaceutical; upfront and milestone payments worth up to $5.85M, as well as sales royalties when the product reaches the market (SEK 0.22, 0.00)

• 02:21 AM ET Feb 20, 2025
  

  Vivesto reports FY EPS (SEK0.07) vs FactSet (SEK0.08) [1 est] (SEK 0.25, 0.00)

• 08:01 AM ET Jan 16, 2025
  

  Vivesto receives approval to initiate a dose-finding study of Paccal Vet in cats (SEK 0.26, 0.00)

• 05:02 AM ET Dec 19, 2024
  

  Vivesto strengthens Cantrixil program with new preclinical results and patent application (SEK 0.27, 0.00)

• 02:04 AM ET Nov 21, 2024
  

  Vivesto reports Q3 EPS (SEK0.02) vs year-ago (SEK0.03) (SEK 0.29, 0.00)